KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
13 06 2019
Historique:
received: 16 10 2018
accepted: 09 05 2019
entrez: 15 6 2019
pubmed: 15 6 2019
medline: 10 7 2019
Statut: epublish

Résumé

Inhibiting the RAS oncogenic protein has largely been through targeting the switch regions that interact with signalling effector proteins. Here, we report designed ankyrin repeat proteins (DARPins) macromolecules that specifically inhibit the KRAS isoform by binding to an allosteric site encompassing the region around KRAS-specific residue histidine 95 at the helix α3/loop 7/helix α4 interface. We show that these DARPins specifically inhibit KRAS/effector interactions and the dependent downstream signalling pathways in cancer cells. Binding by the DARPins at that region influences KRAS/effector interactions in different ways, including KRAS nucleotide exchange and inhibiting KRAS dimerization at the plasma membrane. These results highlight the importance of targeting the α3/loop 7/α4 interface, a previously untargeted site in RAS, for specifically inhibiting KRAS function.

Identifiants

pubmed: 31197133
doi: 10.1038/s41467-019-10419-2
pii: 10.1038/s41467-019-10419-2
pmc: PMC6565726
doi:

Substances chimiques

Antineoplastic Agents 0
Isoenzymes 0
KRAS protein, human 0
Peptide Library 0
Histidine 4QD397987E
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2607

Subventions

Organisme : Medical Research Council
ID : MR/J000612/1
Pays : United Kingdom
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/J000612/1
Pays : International
Organisme : Wellcome Trust (Wellcome)
ID : 099246/Z/12/Z
Pays : International

Références

Biochem J. 2016 Jun 15;473(12):1719-32
pubmed: 27057007
Nat Commun. 2018 Aug 9;9(1):3169
pubmed: 30093669
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2545-2550
pubmed: 30683716
Nat Chem Biol. 2017 Jan;13(1):62-68
pubmed: 27820802
Genes Cancer. 2011 Mar;2(3):261-74
pubmed: 21779497
Sci Transl Med. 2017 Jun 14;9(394):
pubmed: 28615361
Nat Biotechnol. 2006 Jul;24(7):823-31
pubmed: 16823375
Cancer Cell. 2014 Mar 17;25(3):272-81
pubmed: 24651010
Nat Chem Biol. 2013 Jul;9(7):428-36
pubmed: 23685672
Sci Rep. 2017 Jan 09;7:40109
pubmed: 28067274
Cell. 2018 Feb 8;172(4):857-868.e15
pubmed: 29336889
Biophys J. 2010 Dec 15;99(12):4037-46
pubmed: 21156147
Methods Mol Biol. 2012;805:163-90
pubmed: 22094806
Oncogene. 2019 Apr;38(16):2984-2993
pubmed: 30573767
Oncogene. 2008 Apr 24;27(19):2754-62
pubmed: 17998936
Cell. 2018 Jan 25;172(3):578-589.e17
pubmed: 29373830
Elife. 2018 Jul 10;7:
pubmed: 29989546
EMBO J. 2007 Jul 11;26(13):3250-9
pubmed: 17568777
Nat Rev Drug Discov. 2014 Nov;13(11):828-51
pubmed: 25323927
J Am Chem Soc. 2017 Sep 27;139(38):13466-13475
pubmed: 28863262
Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5299-304
pubmed: 22431598
Nat Rev Mol Cell Biol. 2010 May;11(5):329-41
pubmed: 20379207
Biochemistry. 2010 Mar 9;49(9):1970-4
pubmed: 20131908
Science. 2016 Feb 5;351(6273):604-8
pubmed: 26841430
Cell. 2017 Feb 23;168(5):878-889.e29
pubmed: 28235199
Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):7996-8001
pubmed: 26080442
J Mol Biol. 2011 Nov 4;413(4):773-89
pubmed: 21945529
J Mol Med (Berl). 2016 Mar;94(3):253-8
pubmed: 26960760
PLoS One. 2011;6(10):e25711
pubmed: 22046245
Cancer Discov. 2016 Mar;6(3):316-29
pubmed: 26739882
Nat Commun. 2017 Jul 14;8:16111
pubmed: 28706291
Structure. 2015 Jul 7;23(7):1325-35
pubmed: 26051715
Biomol NMR Assign. 2013 Oct;7(2):215-9
pubmed: 22886485
Nature. 1998 Jul 23;394(6691):337-43
pubmed: 9690470
Curr Protoc Cell Biol. 2019 Jun;83(1):e83
pubmed: 30768855
Proc Natl Acad Sci U S A. 2015 May 26;112(21):6625-30
pubmed: 25941399
J Cell Sci. 2016 Apr 1;129(7):1287-92
pubmed: 26985062

Auteurs

Nicolas Bery (N)

Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK.

Sandrine Legg (S)

Antibody Discovery and Protein Engineering, R&D BioPharmaceuticals, Milstein Building Granta Park, Cambridge, CB21 6GH, UK.

Judit Debreczeni (J)

Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Darwin Building, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.

Jason Breed (J)

Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Darwin Building, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.

Kevin Embrey (K)

Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Darwin Building, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.

Christopher Stubbs (C)

Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Darwin Building, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.

Paulina Kolasinska-Zwierz (P)

Antibody Discovery and Protein Engineering, R&D BioPharmaceuticals, Milstein Building Granta Park, Cambridge, CB21 6GH, UK.

Nathalie Barrett (N)

Antibody Discovery and Protein Engineering, R&D BioPharmaceuticals, Milstein Building Granta Park, Cambridge, CB21 6GH, UK.

Rose Marwood (R)

Antibody Discovery and Protein Engineering, R&D BioPharmaceuticals, Milstein Building Granta Park, Cambridge, CB21 6GH, UK.

Jo Watson (J)

Antibody Discovery and Protein Engineering, R&D BioPharmaceuticals, Milstein Building Granta Park, Cambridge, CB21 6GH, UK.

Jon Tart (J)

Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Darwin Building, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.

Ross Overman (R)

Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Darwin Building, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.

Ami Miller (A)

Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK.

Christopher Phillips (C)

Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Darwin Building, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.

Ralph Minter (R)

Antibody Discovery and Protein Engineering, R&D BioPharmaceuticals, Milstein Building Granta Park, Cambridge, CB21 6GH, UK.

Terence H Rabbitts (TH)

Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK. terence.rabbitts@imm.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH